A detailed history of Charles Schwab Investment Management Inc transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 695,947 shares of SNDX stock, worth $11.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
695,947
Previous 654,489 6.33%
Holding current value
$11.2 Million
Previous $13.4 Million 0.3%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$17.93 - $24.81 $743,341 - $1.03 Million
41,458 Added 6.33%
695,947 $13.4 Million
Q2 2024

Aug 12, 2024

BUY
$18.82 - $23.79 $362,887 - $458,718
19,282 Added 3.04%
654,489 $13.4 Million
Q1 2024

May 08, 2024

BUY
$19.71 - $24.57 $1.15 Million - $1.43 Million
58,185 Added 10.08%
635,207 $15.1 Million
Q4 2023

Feb 06, 2024

BUY
$11.39 - $21.67 $803,621 - $1.53 Million
70,555 Added 13.93%
577,022 $12.5 Million
Q3 2023

Nov 08, 2023

BUY
$14.52 - $21.77 $220,065 - $329,946
15,156 Added 3.08%
506,467 $7.35 Million
Q2 2023

Aug 09, 2023

BUY
$19.35 - $22.31 $409,155 - $471,744
21,145 Added 4.5%
491,311 $10.3 Million
Q1 2023

May 11, 2023

BUY
$20.66 - $28.98 $442,640 - $620,896
21,425 Added 4.77%
470,166 $9.93 Million
Q4 2022

Feb 13, 2023

BUY
$20.64 - $26.24 $1.31 Million - $1.67 Million
63,620 Added 16.52%
448,741 $11.4 Million
Q3 2022

Nov 14, 2022

BUY
$18.51 - $24.79 $522,278 - $699,474
28,216 Added 7.91%
385,121 $9.26 Million
Q2 2022

Aug 15, 2022

BUY
$13.64 - $19.48 $212,797 - $303,907
15,601 Added 4.57%
356,905 $6.87 Million
Q1 2022

May 13, 2022

BUY
$14.84 - $22.15 $523,970 - $782,072
35,308 Added 11.54%
341,304 $5.93 Million
Q4 2021

Feb 11, 2022

BUY
$15.23 - $22.47 $52,832 - $77,948
3,469 Added 1.15%
305,996 $6.7 Million
Q3 2021

Nov 16, 2021

BUY
$13.87 - $19.8 $456,267 - $651,340
32,896 Added 12.2%
302,527 $5.78 Million
Q2 2021

Aug 16, 2021

BUY
$13.42 - $25.18 $519,327 - $974,415
38,698 Added 16.76%
269,631 $4.63 Million
Q1 2021

May 17, 2021

BUY
$19.28 - $24.59 $703,045 - $896,674
36,465 Added 18.75%
230,933 $5.16 Million
Q4 2020

Feb 16, 2021

BUY
$15.1 - $26.44 $164,590 - $288,196
10,900 Added 5.94%
194,468 $4.33 Million
Q3 2020

Nov 13, 2020

BUY
$13.39 - $17.48 $1.57 Million - $2.05 Million
117,149 Added 176.38%
183,568 $2.71 Million
Q2 2020

Aug 14, 2020

BUY
$8.94 - $20.98 $95,309 - $223,667
10,661 Added 19.12%
66,419 $985,000
Q1 2020

May 15, 2020

BUY
$6.65 - $12.03 $37,200 - $67,295
5,594 Added 11.15%
55,758 $612,000
Q2 2019

Aug 09, 2019

BUY
$4.9 - $9.31 $63,440 - $120,536
12,947 Added 34.79%
50,164 $468,000
Q1 2019

May 14, 2019

BUY
$4.26 - $6.86 $35,507 - $57,178
8,335 Added 28.86%
37,217 $196,000
Q4 2018

Feb 14, 2019

BUY
$3.6 - $8.42 $16,920 - $39,574
4,700 Added 19.44%
28,882 $129,000
Q3 2018

Nov 13, 2018

SELL
$6.33 - $8.08 $1,379 - $1,761
-218 Reduced 0.89%
24,182 $196,000
Q3 2017

Nov 13, 2017

BUY
$10.9 - $12.73 $265,960 - $310,612
24,400
24,400 $286,000

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $910M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.